abstract |
the present disclosure relates to vaccines and immunogenic compositions against the Zika virus that have one or more antigens from a Zika virus (for example, a clonal isolate of the Zika virus, a Zika virus adapted to non-human cells, etc.). ) and treatment methods and uses. |